Nitrous oxide (Gas) Instructions for Use
ATC Code
N01AX13 (Nitrous oxide)
Active Substance
Nitrous oxide (BP British Pharmacopoeia)
Clinical-Pharmacological Group
Inhalation anesthesia preparation
Pharmacotherapeutic Group
Inhalation anesthetic agent
Pharmacological Action
An agent for inhalation anesthesia. When inhaled, it enters the lungs into the blood by diffusion. It causes anesthesia only at a concentration of 94-95% in the inhaled air, however, using such concentrations is impossible due to the threat of severe hypoxia.
In this regard, a mixture of nitrous oxide and oxygen is usually used in anesthesiology. When using the specified mixture, only the initial level of the stage of surgical anesthesia can be achieved, while sufficient muscle relaxation is absent.
In most cases, Nitrous oxide (in a mixture with oxygen) is used in combination with more potent anesthetic agents and muscle relaxants.
Pharmacokinetics
Nitrous oxide is poorly soluble in blood, quickly reaches high tension in arterial blood, which in turn leads to a faster (compared to other inhalation anesthetic agents) establishment of equilibrium concentrations in the brain and blood and accelerates the induction of anesthesia.
The blood/gas partition coefficient is low – 0.47, the brain/blood partition coefficient is 1.1, the minimum alveolar concentration is more than 100%. It is practically not metabolized in human tissues.
After cessation of inhalation, it is rapidly eliminated from the blood, completely excreted within 10-15 minutes through the respiratory tract unchanged, which causes a rapid recovery from anesthesia.
Indications
For inhalation anesthesia during surgical interventions, gynecological operations. For labor analgesia. Pathological conditions accompanied by pain that is not relieved by traditional means, including acute coronary insufficiency, myocardial infarction, acute pancreatitis.
ICD codes
| ICD-10 code | Indication |
| I21 | Acute myocardial infarction |
| I24.9 | Acute ischemic heart disease, unspecified |
| K85 | Acute pancreatitis |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| BA41.Z | Acute myocardial infarction, unspecified |
| BA4Z | Acute ischemic heart disease, unspecified |
| DC31.Z | Acute pancreatitis, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Gas
It is used in a mixture with oxygen using special gas anesthesia machines. Usually, they start with a mixture containing 70-80% nitrous oxide and 30-20% oxygen, then the amount of oxygen is increased to 40-50%.
If the required depth of anesthesia cannot be achieved at a nitrous oxide concentration of 70-75%, more potent anesthetic agents are added, including halothane, diethyl ether, barbiturates.
Adverse Reactions
From the hematopoietic system: with prolonged use, megaloblastic anemia, hemopoiesis disorders are possible.
From the peripheral nervous system: with prolonged use, peripheral neuropathy is possible.
Contraindications
As a therapeutic anesthesia in severe diseases of the nervous system, chronic alcoholism, state of alcohol intoxication (excitation, hallucinations are possible).
Use in Pregnancy and Lactation
It is used for labor analgesia.
If it is necessary to use during lactation, breastfeeding should be discontinued.
Pediatric Use
The dose is set individually.
Geriatric Use
The dose is set individually.
Special Precautions
Use with caution in severe hypoxia and impaired gas diffusion in the lungs.
Nitrous oxide does not cause irritation of the respiratory tract.
Drug Interactions
It is assumed that with simultaneous use of nitrous oxide and methotrexate, the adverse effect of the latter is enhanced. According to other data, Nitrous oxide enhances the therapeutic effect of methotrexate.
Storage Conditions
Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Compressed gas: cylinders 0.62 kg, 1.24 kg, 3.1 kg, 6.2 kg, 24.8 kg, 31 kg cylinders
Marketing Authorization Holder
Linde Gas Rus, JSC (Russia)
Dosage Form
| Nitrous oxide | Compressed gas: cylinders 0.62 kg, 1.24 kg, 3.1 kg, 6.2 kg, 24.8 kg, 31 kg cylinders |
Dosage Form, Packaging, and Composition
Compressed gas colorless, odorless.
| 1 cylinder | |
| Nitrous oxide medical* | 100% |
* Nitrous oxide medical – 98%
0.62 kg – cylinders.
1.24 kg – cylinders.
3.1 kg – cylinders.
6.2 kg – cylinders.
24.8 kg – cylinders.
31 kg – cylinders.
Compressed gas 6.2 kg: cylinders
Marketing Authorization Holder
Medgazservis Trading House LLC (Russia)
Dosage Form
| Nitrous oxide | Compressed gas 6.2 kg: cylinders |
Dosage Form, Packaging, and Composition
| compressed gas | 1 cylinder |
| Nitrous oxide | 6.2 kg |
6.2 kg – cylinders.
6.2 kg – metal cylinders.
Compressed gas 6.2 kg: 10 l cylinders
Marketing Authorization Holder
Styrolbiopharm LLC (Ukraine)
Dosage Form
| Nitrous oxide | Compressed gas 6.2 kg: 10 l cylinders |
Dosage Form, Packaging, and Composition
| compressed gas | 1 cylinder |
| Nitrous oxide | 6.2 kg |
6.2 kg – metal cylinders with a concave base with a volume of 10 l.
